Organization (Industry)
BRISTOL-MYERS SQUIBB COMPANY
ClinicalTrials.gov lists BRISTOL-MYERS SQUIBB COMPANY as lead sponsor of 1,624 trials, counting the companies grouped under it. BRISTOL-MYERS SQUIBB COMPANY itself has 816 active development programs and 256 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 79 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 90 in 2026 and about 89 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (20 to 100), forecasts made part-way through the year were typically off by about 18 percent and ran about 14 percent low against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. 2 trials are registered to start in 2027 or later.
Logo Bristol-Myers Squibb, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers BRISTOL-MYERS SQUIBB COMPANY and 6 companies grouped under it: 1,624 lead-sponsored trials (1,560 its own, 64 in the grouped companies) and 21 legal-entity registrations (18 its own, 3 in the grouped companies).
Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.
Companies grouped under this page (6)
Shown in this order: most lead trials first.
| Company | Lead trials | Legal entities |
|---|---|---|
| Mirati Therapeutics (United States) | 51 | 1 |
| Turning Point Therapeutics, Inc. | 9 | 0 |
| Adnexus, A Bristol-Myers Squibb R&D Company | 3 | 0 |
| 2seventy bio | 1 | 0 |
| Bristol-Myers Squibb Services Unlimited Company | 0 | 0 |
Showing 5 of 6 member companies.
Disease areas (506)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Multiple Myeloma | 294 |
| Lung Neoplasms | 285 |
| Lymphoma | 212 |
| Carcinoma, Non-Small-Cell Lung | 204 |
| Melanoma | 195 |
Showing 5 of 506 disease areas.
Trials by start year as sponsor or collaborator (32)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 2 trials are registered to start in 2027 or later, and not listed here.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 79 |
| 2025 | 89 |
| 2024 | 80 |
| 2023 | 123 |
| 2022 | 103 |
| 2021 | 108 |
| 2020 | 125 |
| 2019 | 180 |
| 2018 | 190 |
| 2017 | 189 |
Showing 10 of 32 years.
Prediction, not a registry value: median of 36 months from start to primary completion across 80 trials still running at the 2026-10-09 snapshot; registered median of 19 months across 1,283 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (816)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| CARBOPLATIN | Lung Neoplasms | Phase 3 | 28 |
| CISPLATIN | Lung Neoplasms | Phase 3 | 20 |
| PEMETREXED | Lung Neoplasms | Phase 3 | 19 |
| CARBOPLATIN | Carcinoma, Non-Small-Cell Lung | Phase 3 | 20 |
| PEMETREXED | Carcinoma, Non-Small-Cell Lung | Phase 3 | 16 |
Showing 5 of 816 active programs.
Approved assets (256)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| NIVOLUMAB | 212 |
| IPILIMUMAB | 128 |
| Abatacept | 59 |
| DASATINIB | 50 |
| Apixaban | 41 |
Showing 5 of 256 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 51% hit target (n=501) | 40% on time (n=502) |
Journals published in (792)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 263 |
| Blood | 215 |
| The New England journal of medicine | 203 |
| Circulation | 83 |
| The Lancet. Oncology | 83 |
Showing 5 of 792 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 4,673 | 520 | 2025-12-30 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 48,194,000,000 | 7,054,000,000 | 9,951,000,000 |
| 2024 | 48,300,000,000 | -8,948,000,000 | 11,159,000,000 |
| 2023 | 45,006,000,000 | 8,025,000,000 | 9,299,000,000 |
| 2022 | 46,159,000,000 | 6,327,000,000 | 9,509,000,000 |
| 2021 | 46,385,000,000 | 6,994,000,000 | 10,195,000,000 |
| 2020 | 42,518,000,000 | -9,015,000,000 | 10,048,000,000 |
| 2019 | 26,145,000,000 | 3,439,000,000 | 6,148,000,000 |
| 2018 | 22,561,000,000 | 4,920,000,000 | 6,332,000,000 |
| 2017 | 20,776,000,000 | 1,007,000,000 | 6,468,000,000 |
| 2016 | 19,427,000,000 | 4,457,000,000 | 5,012,000,000 |
Showing 10 of 11 fiscal years.
Financing and grant events (43)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-11-18 | Debt financing | not disclosed | Sec extracted |
| 2025-11-17 | Debt financing | not disclosed | Sec extracted |
| 2025-11-10 | Debt financing | not disclosed | Sec extracted |
| 2025-11-10 | Debt financing | not disclosed | Sec extracted |
| 2025-11-07 | Debt financing | not disclosed | Edgar offerings |
Showing 5 of 43 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 30 |
FDA recalls (5)
Shown in this order: most recent first.
| Product | Classification | Initiated |
|---|---|---|
| Opdualag (nivolumab and relatlimab-rmbw) injection, 240 mg and 80 mg/20 mL (12mg and 4mg/mL),Single Dose Vial, RX Only, Bristol-Myers Squibb Company, Princeton, NJ 08543, NDC 0003-7125-11 | Class II | 2025-10-21 |
| EliquisTablets 5mg, 60 count bottle, Rx Only, Marketed by: Bristol-Meyers Squibb Company Princeton, NJ 08543 USA and Pfizer Inc. New York, NY 10017 USA, NDC 0003-0894-21 | Class I | 2017-06-05 |
| BiCNU (Carmustine for injection) 100 mg and Diluent Rx Only BiCNU manufactured by: Ben Venue Laboratories, Inc. Bedford, OH 44146 Diluent manufactured by: Luitpold Pharmaceuticals, Inc. Shirley, NY 11967 Distributed by: Bristol-Meyers Squibb Company Princeton, NJ 08543 USA Made in USA NDC 0015-3012-18 NDC 0015-3012-60 | Class I | 2012-08-29 |
| Kombiglyze XR (saxagliptin and metformin HCl extended-release) tablets, Physician Sample-Not For Sale, 6 Tablets per Carton, 2.5 mg/1000 mg, Rx only, Manufactured By: Bristol-Myers Squibb Company, Princeton NJ 08543, USA, Marketed By: Bristol-Myers Squibb Company, Princeton NJ 08543, USA and AstraZeneca Pharmaceuticals LP, Wilmington DE 19850. | Class II | 2012-06-05 |
| Kombiglyze XR (saxagliptin and metformin HCl extended-release) tablets, Physician Sample-Not For Sale, 7 Tablets per Carton, 5 mg/500 mg, Rx only, Manufactured By: Bristol-Myers Squibb Company, Princeton NJ 08543, USA, Marketed By: Bristol-Myers Squibb Company, Princeton NJ 08543, USA and AstraZeneca Pharmaceuticals LP, Wilmington DE 19850. | Class II | 2012-06-05 |
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 40 | 2026-08-06 |
Manufacturing and distribution sites (2)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Bristol-Myers Squibb Company | Devens, US | FDA, Health Canada | |
| Bristol-Myers Squibb Company | Mount Vernon, US | Health Canada |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Organization relationships (706)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Government of the United States of America | Co sponsors trial with | 100 |
| M.D. Anderson Cancer Center | Co sponsors trial with | 72 |
| GSK plc | Co sponsors trial with | 31 |
| Ono Pharmaceutical (Japan) | Co sponsors trial with | 29 |
| Dana-Farber Cancer Institute | Co sponsors trial with | 26 |
Showing 5 of 706 relationships.
Latest dated events (8,711)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2027-02-10 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-02-03 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-01-05 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-01-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-12-31 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 8,711 events.
CLIA clinical laboratory certificates (9)
Shown in this order: active first, then certificate type.
| Lab | Certificate | Status |
|---|---|---|
| BRISTOL MYERS SQUIBB | Certificate of waiver | Active |
| BRISTOL MYERS SQUIBB | Certificate of waiver | Active |
| BRISTOL MYERS SQUIBB | Certificate of waiver | Active |
| BRISTOL MYERS SQUIBB | Certificate of waiver | Active |
| BRISTOL MYERS SQUIBB | Certificate of waiver | Active |
Showing 5 of 9 certificates.
Biomarker capability evidence (8,722)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ABCC6 | Trial sponsor | Named in trial inclusion criteria |
| ABCC6 | Trial sponsor | Named in trial inclusion criteria |
| ABCD2 | Trial collaborator | Named in trial inclusion criteria |
| ABL1 | Trial sponsor | Named in trial inclusion criteria |
| ABL1 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 8,722 evidence rows.
On Scientist.com
BRISTOL-MYERS SQUIBB COMPANY is listed as a research supplier in the Scientist.com network.
Service areas
ach Overview Platform Cardiomyopathy Programs MyoKardia is developing a pipeline of novel small molecule therapeutics that address key clinical needs for patients with genetic heart disease. The company’s first programs include hypertrophic and dilated cardiomyopathy, which together afflict approximately 1 million people in the United States, and for which no novel therapeutics have been brought to market in over a decade. MyoKardia’s proprietary drug discovery platform brings together advances from the fields of cardiovascular genomics and heart muscle biology to enable its scientists...
Show the full description
ach
Overview
Platform
Cardiomyopathy
Programs
MyoKardia is developing a pipeline of novel small molecule therapeutics that address key clinical needs for patients with genetic heart disease. The company’s first programs include hypertrophic and dilated cardiomyopathy, which together afflict approximately 1 million people in the United States, and for which no novel therapeutics have been brought to market in over a decade.
MyoKardia’s proprietary drug discovery platform brings together advances from the fields of cardiovascular genomics and heart muscle biology to enable its scientists to target certain heart disease 'at its source.' This genetically targeted approach has the potential to revolutionize the treatment of cardiomyopathies, and ultimately a broader spectrum of cardiovascular disease, including heart failure.
- Website
- www.myokardia.com
Not on this page
Checked, with nothing recorded for this organization: fda warning letters, fda untitled letters, and biomarkers this organization publishes on.
Work with MyoKardia on Scientist.com
For prices, more details, or to contact MyoKardia, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.